<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03853447</url>
  </required_header>
  <id_info>
    <org_study_id>H-18017281</org_study_id>
    <nct_id>NCT03853447</nct_id>
  </id_info>
  <brief_title>Fibro-inflammatory Progression From Acute to Chronic Pancreatitis</brief_title>
  <official_title>Characterization of Fibro-inflammation During Progression From Acute to Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital, Hvidovre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational prospective study evaluating the developement of chronic pancreatitis based on
      imaging modalities as well as biochemical markers of inflammation, fibrosis and oxidative
      stress.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic pancreatitis (CP) represents the end-stage of a continuous disease process evolving
      from acute pancreatitis (AP), over recurrent acute pancreatitis (RAP). Due to the
      irreversible nature of CP, early detection and prevention is key. The study uses
      state-of-the-art imaging modalities as well as biochemical markers of to evaluate fibrosis
      progression in patients with pancreatitis.

      The included participants have either first time AP, RAP, early CP with preserved pancreatic
      exocrine and endocrine function or end-stage CP with exocrine insufficiency. Included
      patients will be followed prospectively for 15 years with advanced MRI and contrast enhanced
      EUS with elastography, assessment of endocrine and exocrine pancreatic function, biochemical
      and nutritional assessment, and evaluation of pain processing using quantitative sensory
      testing. Blood for a biobank will be obtained. The purpose of the biobank is to allow
      analyses of potential biomarkers for the progression of disease eventually leading to CP.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2041</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2040</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrosis progression on endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI)</measure>
    <time_frame>15 years</time_frame>
    <description>Progression of fibrosis in the pancreas based on either EUS or MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lean body mass assessed using bioimpedance</measure>
    <time_frame>15 years</time_frame>
    <description>Body composition focusing on lean body mass will be assessed using bioimpedance</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pancreatitis</condition>
  <condition>Acute Pancreatitis</condition>
  <condition>Recurrent Pancreatitis</condition>
  <condition>Chronic Pancreatitis</condition>
  <condition>Inflammation</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Diagnostic imaging</arm_group_label>
    <description>The progression of fibrosis will be assessed based on diagnostic imaging of thre subgroups including
Patients with chronic pancreatitis (CP; N=50) of any aetiology, except gallstones, based on MANNHEIM.
Patients with their first attack of acute pancreatitis (AP; N=50) of any aetiology except gallstones using the revised Atlanta criteria for AP.
Patients with recurrent AP (RAP; N=50) except gallstones, defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic imaging</intervention_name>
    <description>MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS</description>
    <arm_group_label>Diagnostic imaging</arm_group_label>
    <other_name>MRI and EUS</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum and buffy coat
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CP, AC pr RAP who are not:

          1. Pregnant or lactating patients

          2. Contraindications to magnetic resonance imaging (MRI) or endoscopic ultrasound

          3. Known chronic liver disease, chronic renal failure, malignancy, chronic inflammatory
             bowel syndrome, chronic obstructive lung disease, pulmonary fibrosis.

          4. Treatment with anti-inflammatory drugs of any kind at the time of inclusion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CP (N=50) of any aetiology except gallstone induced CP: CP will be
             diagnosed based on MANNHEIM criteria .

          -  Cohort 2: Patients with their first attack of AP of any aetiology except gallstone
             induced AP (N=50). The revised Atlanta criteria for acute pancreatitis will be used as
             diagnostic criteria.

          -  Cohort 3: Patients with RAP (N=50) except gallstone induced RAP. RAP is defined as two
             or more cases of AP as diagnosed by the revised Atlanta Criteria.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Srdan Novovic, PhD</last_name>
    <phone>38623862</phone>
    <email>srdan.novovic@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lise L Gluud, MSc</last_name>
    <phone>+45 38621964</phone>
    <email>lise.lotte.gluud.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gastrounit, Copenhagen University Hospital Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <state>Capital Region Denmark</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise L Gluud, MD</last_name>
      <phone>+4538621964</phone>
      <email>lise.lotte.gluud.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Srdan Novovic, MD</last_name>
      <phone>+38623862</phone>
      <email>srdan.novovic@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology &amp; Hepatology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soeren Schou Olesen, PhD</last_name>
      <phone>+45 97 66 00 00</phone>
      <email>soso@dcm.aau.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abdominal Centre, Bispebjerg University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Nannestad Joergensen, PhD</last_name>
      <phone>+45 21 32 02 41</phone>
      <email>lars.nannestad.joergensen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital, Hvidovre</investigator_affiliation>
    <investigator_full_name>Lise Gluud</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

